Improving the survival of patients with osteosarcoma has long proved challenging, although
the treatment of this disease is on the precipice of advancement. The increasing feasibility of …

Abstract High-dose methotrexate (HDMTX), defined as a dose higher than 500 mg/m2, is
used to treat a range of adult and childhood cancers. Although HDMTX is safely …

Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and
young adults. Before 1970, treatment primarily included surgical resection. However, the …

Long-term outcome for patients with high-grade osteosarcoma has improved with the
addition of systemic chemotherapy, but subsequent progress has been less marked …

Osteosarcoma is the most common malignant bone tumor, currently treated with pre-and
postoperative chemotherapy in association with the surgical removal of the tumor. About 15 …

PURPOSE: To define prognostic factors for response and long-term outcome for a wide
spectrum of osteosarcomas, extending well beyond those of the typical young patient with …

Background High-grade osteosarcoma is a primary malignant bone tumour mainly affecting
children and young adults. The European and American Osteosarcoma Study (EURAMOS) …

Despite significant advancements in the diagnosis and treatment of osteosarcoma to date,
overall survival has remained relatively constant for over 2 decades. The challenge in …

Purpose: To determine demographic data and define prognostic factors for long-term
outcome in patients presenting with high-grade osteosarcoma of bone with clinically …

AIM: Since the introduction of chemotherapy, survival in localised high-grade osteosarcoma
has improved considerably. However, there is still no worldwide consensus on a standard …